PI3K in CLL: are 2 isoforms better than 1?
PI3K in CLL: are 2 isoforms better than 1?
In this issue of Blood Dong et al present a series of experiments with the novel B cell receptor kinase inhibitor IPI-145 (PI3K?/? inhibitor) and show CLL samples resistant to ibrutinib remain sensitive to killing by this agent.
3508-3510
Steele, Andrew J.
4349f6aa-2e3a-49a8-be73-7716056ae089
4 December 2014
Steele, Andrew J.
4349f6aa-2e3a-49a8-be73-7716056ae089
Abstract
In this issue of Blood Dong et al present a series of experiments with the novel B cell receptor kinase inhibitor IPI-145 (PI3K?/? inhibitor) and show CLL samples resistant to ibrutinib remain sensitive to killing by this agent.
Text
__soton.ac.uk_ude_PersonalFiles_Users_as1r10_mydocuments_Andy Southampton hc_Electronic papers_My papers_Steele Aj 2 isoforms 2014.pdf
- Version of Record
Restricted to Repository staff only
Request a copy
Text
Steele IPI145 inside blood commentary vs3.docx
- Author's Original
More information
Published date: 4 December 2014
Organisations:
Cancer Sciences
Identifiers
Local EPrints ID: 373201
URI: http://eprints.soton.ac.uk/id/eprint/373201
ISSN: 0006-4971
PURE UUID: c23b7367-1bed-4cc1-8861-eabd8cdff574
Catalogue record
Date deposited: 12 Jan 2015 12:21
Last modified: 15 Mar 2024 03:39
Export record
Altmetrics
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics